SCHEMBL27193644

SCHEMBL27193644

COc1ccc(C(OC[C@H]2O[C@@H](n3cnc4c(NC(C)C)ncnc43)C(F)C2OP(OCCC#N)N(C(C)C)C(C)C)(c2ccccc2)c2ccc(OC)cc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TYMP P19971 5/20 0.42
▸ PRKAG1 P54619 1/20 0.40
▸ PRKAA1 Q13131 1/20 0.40
▸ PRKAB1 Q9Y478 1/20 0.40
▸ ADORA1 P30542 2/20 0.36
▸ ADORA3 P0DMS8 2/20 0.35
▸ ADORA2A P29274 2/20 0.35
▸ TP53 P04637 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ ALOX12 P18054 1/20 0.35
▸ NFKB1 P19838 1/20 0.35
▸ HIF1A Q16665 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ PMP22 Q01453 1/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ ADORA2B P29275 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ RXFP1 Q9HBX9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27193645 0.95 TYMP (0.42) TYMPPRKAG1PRKAA1PRKAB1ADORA1
SCHEMBL29644745 0.92 TYMP (0.42) TYMPPRKAG1PRKAA1PRKAB1ADORA1
SCHEMBL29471806 0.92 TYMP (0.42) TYMPPRKAG1PRKAA1PRKAB1ADORA1
SCHEMBL18927153 0.92 TYMP (0.42) TYMPPRKAG1PRKAA1PRKAB1ADORA1
SCHEMBL18511052 0.92 TYMP (0.42) TYMPPRKAG1PRKAA1PRKAB1ADORA1
SCHEMBL27193642 0.91 TYMP (0.49) TYMPPRKAG1PRKAA1PRKAB1ADORA1
SCHEMBL29913291 0.88 TYMP (0.40) TYMPPRKAG1PRKAA1PRKAB1ADORA1
SCHEMBL30601047 0.88 TYMP (0.43) TYMPADORA1
SCHEMBL29793200 0.87 TYMP (0.42) TYMPADORA1ADORA2ATP53CYP3A4
SCHEMBL18822706 0.87 TYMP (0.42) TYMPPRKAG1PRKAA1PRKAB1ADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240116973-A1 MODIFIED OLIGONUCLEOTIDES ALNYLAM PHARMACEUTICALS, INC. (US) 2024-04-11 — — US disclosed
EP-4277636-A1 MODIFIED OLIGONUCLEOTIDES Alnylam Pharmaceuticals, Inc. (US) 2023-11-22 — — EP disclosed
WO-2022155418-A9 MODIFIED OLIGONUCLEOTIDES ALNYLAM PHARMACEUTICALS, INC. (US) 2023-03-09 — — WO disclosed
WO-2022155418-A1 MODIFIED OLIGONUCLEOTIDES ALNYLAM PHARMACEUTICALS, INC. (US) 2022-07-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240116973-A1 MODIFIED OLIGONUCLEOTIDES ADAR, EIF2AK2, TRDMT1 TYMP 435/4885PRKAG1 749/4885PRKAA1 1419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback